Plain-English translation of NCT07053293 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Type 2 Diabetes research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This research study is testing how empagliflozin, a diabetes medication, affects the way your body produces glucose and how your nervous system responds to the medication. Researchers will measure these effects by giving you the medication and using special tracers (safe, radioactive markers) to track what happens inside your body. The goal is to understand exactly how this treatment works at a chemical level.
Doctors know this medication helps lower blood sugar in people with type 2 diabetes, but they don't fully understand all the ways it works in your body. This study will help researchers figure out the detailed mechanisms so they can better predict who will benefit most from this treatment and potentially develop even better diabetes medications.
You likely qualify if…
You likely don't qualify if…
You would come to the research center for two study visits, performed in random order. At each visit, you'll arrive early in the morning after fasting, and researchers will give you special tracer infusions through an IV to track how your body produces glucose and processes fats. You'll take a single dose of the medication during the study, and researchers will measure your nervous system response before and after taking it. Each visit lasts several hours and involves blood sampling throughout the day.
AI-generated summary from trial data · Jun 28, 2026 · Not medical advice
United States